These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28574876)

  • 1. Utility of Follow-up Dopamine Transporter SPECT With 123I-FP-CIT in the Diagnostic Workup of Patients With Clinically Uncertain Parkinsonian Syndrome.
    Apostolova I; Taleb DS; Lipp A; Galazky I; Kupitz D; Lange C; Makowski MR; Brenner W; Amthauer H; Plotkin M; Buchert R
    Clin Nucl Med; 2017 Aug; 42(8):589-594. PubMed ID: 28574876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FP-CIT- and IBZM-SPECT in Corticobasal Syndrome: Results from a Clinical Follow-Up Study.
    Hammesfahr S; Antke C; Mamlins E; Beu M; Wojtecki L; Ferrea S; Dinkelbach L; Moldovan AS; Schnitzler A; Müller HW; Südmeyer M
    Neurodegener Dis; 2016; 16(5-6):342-7. PubMed ID: 26978429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [123I]FP-CIT SPECT in Clinically Uncertain Parkinsonism Predicts Survival: A Data-Driven Analysis.
    Frings L; Henninger F; Treppner M; Köber G; Boeker M; Hellwig S; Buchert R; Meyer PT
    J Parkinsons Dis; 2020; 10(4):1457-1465. PubMed ID: 33044193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes.
    Albert NL; Unterrainer M; Diemling M; Xiong G; Bartenstein P; Koch W; Varrone A; Dickson JC; Tossici-Bolt L; Sera T; Asenbaum S; Booij J; Kapucu LÖ; Kluge A; Ziebell M; Darcourt J; Nobili F; Pagani M; Sabri O; Hesse S; Borght TV; Van Laere K; Tatsch K; la Fougère C
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1315-22. PubMed ID: 26780619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases.
    Sixel-Döring F; Liepe K; Mollenhauer B; Trautmann E; Trenkwalder C
    J Neurol; 2011 Dec; 258(12):2147-54. PubMed ID: 21547379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia.
    Gil-Navarro S; Lomeña F; Cot A; Lladó A; Montagut N; Castellví M; Bosch B; Rami L; Antonell A; Balasa M; Pavia J; Iranzo A; Molinuevo JL; Sánchez-Valle R
    Eur J Neurol; 2013 Nov; 20(11):1459-e126. PubMed ID: 23679075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No impact of attenuation and scatter correction on the interpretation of dopamine transporter SPECT in patients with clinically uncertain parkinsonian syndrome.
    Schiebler T; Apostolova I; Mathies FL; Lange C; Klutmann S; Buchert R
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3302-3312. PubMed ID: 37328621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved visual [(123)I]FP-CIT SPECT interpretation for evaluation of parkinsonism by visual rating of parametric distribution volume ratio images.
    Meyer PT; Winz OH; Dafotakis M; Werner CJ; Krohn T; Schäfer WM
    Q J Nucl Med Mol Imaging; 2011 Jun; 55(3):301-9. PubMed ID: 21532542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes.
    Uyama N; Otsuka H; Shinya T; Otomi Y; Harada M; Sako W; Izumi Y; Kaji R; Watanabe Y; Takashi S; Kunikane Y
    Nucl Med Commun; 2017 Jun; 38(6):487-492. PubMed ID: 28410288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study.
    Tinazzi M; Morgante F; Matinella A; Bovi T; Cannas A; Solla P; Marrosu F; Nicoletti A; Zappia M; Luca A; Di Stefano A; Morgante L; Pacchetti C; Minafra B; Sciarretta M; Dallocchio C; Rossi S; Ulivelli M; Ceravolo R; Frosini D; Cipriani A; Barbui C
    Schizophr Res; 2014 Feb; 152(2-3):344-9. PubMed ID: 24369987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of the combined use of
    Matsusue E; Fujihara Y; Tanaka K; Aozasa Y; Shimoda M; Nakayasu H; Nakamura K; Ogawa T
    Acta Radiol; 2019 Feb; 60(2):230-238. PubMed ID: 29804474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
    Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
    Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism.
    Mäkinen E; Joutsa J; Johansson J; Mäki M; Seppänen M; Kaasinen V
    J Neural Transm (Vienna); 2016 Nov; 123(11):1309-1318. PubMed ID: 27324804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients.
    Plotkin M; Amthauer H; Klaffke S; Kühn A; Lüdemann L; Arnold G; Wernecke KD; Kupsch A; Felix R; Venz S
    J Neural Transm (Vienna); 2005 May; 112(5):677-92. PubMed ID: 15375677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study.
    Pirker W; Djamshidian S; Asenbaum S; Gerschlager W; Tribl G; Hoffmann M; Brücke T
    Mov Disord; 2002 Jan; 17(1):45-53. PubMed ID: 11835438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: feasibility, optimization and validation.
    Greco A; Zannetti A; Pappatà S; Albanese S; Coda AR; Ragucci M; Nardelli A; Brunetti A; Cuocolo A; Salvatore M
    Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):112-117. PubMed ID: 26329495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease.
    Kahraman D; Eggers C; Schicha H; Timmermann L; Schmidt M
    J Neurol; 2012 Feb; 259(2):251-60. PubMed ID: 21750954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism.
    Van Laere K; Everaert L; Annemans L; Gonce M; Vandenberghe W; Vander Borght T
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1367-76. PubMed ID: 18385998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 123I-FP-CIT brain SPECT (DaTSCAN) imaging in the diagnosis of patients with movement disorders--first results.
    Jauković L; Ilić TV; Dopudja M; Ajdinović B
    Vojnosanit Pregl; 2012 Feb; 69(2):157-62. PubMed ID: 22500370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine transporter imaging and the effects of deep brain stimulation in patients with Parkinson's disease.
    Lokkegaard A; Werdelin LM; Regeur L; Karlsborg M; Jensen SR; Brødsgaard E; Madsen FF; Lonsdale MN; Friberg L
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):508-16. PubMed ID: 17096096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.